PreveCeutical Medical Inc.

PreveCeutical Announces Possible Viral Prevention Program Using CBD Sol-gel

PreveCeutical Retains Patent Legal Team

PreveCeutical Announces Further Updates to the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program

PreveCeutical Announces Positive Results Following a Preliminary Safety Evaluation of Sol-Gel Formulations When Applied to Human Nasal Tissue

PreveCeutical Announces Successful Completion from its Design, Synthesis and Preliminary Evaluation of Novel Designed Peptides Derived from Caribbean Blue Scorpion Venom in a Cell-Based Brain Cancer Model

PreveCeutical Receives $616,802 AUD Research and Development Tax Incentive Cash Refund

PreveCeutical Announces the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program

PreveCeutical Reaches Milestone in Research Program for Development of Non-Addictive Analgesics

PreveCeutical Grants Asterion Option to Purchase up to a 51% Interest in Sol-Gel Intellectual Property

PreveCeutical Grants Asterion Option to Purchase up to a 51% Interest in Sol-Gel Intellectual Property

PreveCeutical Successfully Incorporates Medicinal Cannabis Extracts into the Sol-Gel Drug Delivery System

PreveCeutical Announces Further Positive Results from its Dual Gene Therapy Research Program

PreveCeutical Secures $300,000 Loan and Resignation of a Director

PreveCeutical Granted Approval to Acquire and Use Human Mucosal Tissue for Final Phase of Sol-Gel Program

PreveCeutical Partnership Leads to Two New Patent Filings

PreveCeutical Files Application to Human Ethics Committee to Acquire Human Tissue for the Final Phase of the Sol-Gel Program

PreveCeutical Announces Further Results from its Preliminary Screening of Peptides Derived from Blue Scorpion Venom in a Cell-Based Brain Cancer Model

PreveCeutical Announces Default Judgment Against JCN Capital Corp.

Asterion Welcomes Australian Government Awarding of Major Project Status for its Toowoomba Medicinal Cannabis Project

Asterion Welcomes Australian Government Awarding of Major Project Status for its Toowoomba Medicinal Cannabis Project

PreveCeutical Announces Default Judgment Against Essos Corporate Services Inc. and Detona Capital Corp.

PreveCeutical Announces Preliminary Screening Results of Peptides Derived From Blue Scorpion Venom in a Cell-Based Brain Cancer Model

PreveCeutical Announces Appointment of Dr. Makarand Jawadekar as President

PreveCeutical to Explore Partnerships with Pharmaceutical and Biotechnology Companies for the Co-Development of its Sol-Gel System

PreveCeutical Provides Update on the Dual Gene Therapy Program

PreveCeutical Provides Update on Research Program for Development of Non-Addictive Analgesics

PreveCeutical Files Notice of Civil Claim Against the BridgeMark Group

PreveCeutical Converts Acidic Phytocannabinoids to Neutral Form and Doubles Contents of Fingerprinted Cannabis Extract Library

PreveCeutical Confirms Encouraging Results from Sol-gel Applicator Trials for Achieving Direct Nose-to-Brain Delivery in an Adult Human Nasal Cast

PreveCeutical Announces LOI with Crushedit LLC to Supply CBD Isolate for Expected Sale Proceeds of $16.25 Million